Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab 15 September
CAPVAXIVE® Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease 11 September
